TLRY Stock Loses 17% in Three Months: Should You Buy, Hold or Sell?

Tilray's fiscal 2026 revenue rose 11% to a record $915.5 million and adjusted EBITDA increased 11% to $61.1 million, while fiscal 2027 EBITDA guidance is $68-$75 million. However, adjusted gross margin was flat at 29%, operating and adjusted free cash flow remained negative, and the company raised $87 million through an ATM program, diluting shareholders. TLRY shares are down 54% year to date, and fiscal 2028 consensus EPS has deteriorated from a $0.10 profit forecast to an $0.18 loss, supporting a hold/wait-and-see stance.

Analysis

TLRY is being valued as a cannabis reopening option while an increasing share of its economics resembles low-margin distribution and acquired beverage operations. That mix can support revenue scale without improving per-share earnings, particularly when working-capital needs rise faster than EBITDA and equity issuance funds integration. The key second-order issue is that a larger revenue base may lower, rather than raise, the multiple unless management proves that CC Pharma cross-selling produces measurable gross-margin lift and BrewDog stops consuming cash.

European medical cannabis is the strategically valuable asset, but it is unlikely to remain a TLRY-exclusive growth pool. ACB has greater pure-play exposure to this higher-margin channel, while CURA's interest in Aurora signals that regulated European capacity and distribution may attract strategic buyers. If consolidation tightens supply, TLRY benefits; if competitors use scale to price aggressively, TLRY's broad portfolio becomes a disadvantage because distribution and beer margins offer limited cushion against cannabis deflation.

Near-term downside is likely capped by regulatory and retail-driven cannabis beta, making an outright TLRY short unattractive after substantial underperformance. Over the next 1-3 months, the relevant catalyst is not revenue but evidence of positive operating cash flow, inventory discipline, and no further ATM dependence; absent these, consensus estimates can continue to reset lower. The bearish thesis is falsified by two consecutive quarters of positive free cash flow alongside EBITDA tracking above the high end of guidance without material share-count growth; a U.S. rescheduling or legalization surprise is the principal event risk to any relative-value short.

Key Decisions for Investors

• Maintain no standalone long in TLRY until the next two quarterly reports establish positive operating cash flow and stable diluted share count; revenue-run-rate messaging alone is not a buy trigger.
• Initiate a 3-6 month relative-value position: long ACB / short TLRY in equal cannabis-beta-adjusted dollars. The setup captures ACB's European strategic-value and potential corporate-action optionality against TLRY's execution and dilution risk; exit if TLRY demonstrates positive free cash flow for two consecutive quarters or if ACB bid-related upside is resolved.
• For existing TLRY exposure, use any regulation-led rally to reduce rather than add unless the rally coincides with a raised EBITDA outlook and explicit free-cash-flow timing. A 15-20% tactical rebound without estimate revisions is likely retail-beta, not a fundamental rerating.
• Monitor CC Pharma gross margin, beverage working capital, and quarterly weighted-average shares as hard alerts. A meaningful margin improvement without incremental working-capital consumption would justify revisiting TLRY as a 6-18 month turnaround; another equity raise would reinforce the short leg of the pair.